methyl 6-(4-aminobenzamido)hexanoate | 842949-90-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 6-(4-aminobenzamido)hexanoate
• 英文别名: Methyl 6-(4-aminobenzoylamino)hexanoate；methyl 6-[(4-aminobenzoyl)amino]hexanoate
• CAS: 842949-90-0
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: JTXQQWCDNBYCOW-UHFFFAOYSA-N

物化性质

• 沸点：
  459.7±30.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 6-(4-aminobenzamido)hexanoate 在 羟胺 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 30.0h， 生成 7-cyclopentyl-2-((4-((6-(hydroxyamino)-6-oxohexyl)-carbamoyl)phenyl)amino)-N,N-dimethyl-7H-pyrrolo[2,3-d]-pyrimidine-6-carboxamide
  参考文献：
  名称：

  Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer

  摘要：

  A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo [2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyo ctan ediamide (6e) was discovered. The lead compound 6e with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound 6e showed excellent selectivity and specificity. Compound 6e induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with 6e showed significant antitumor efficacy. The insight into mechanisms of 6e indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound 6e could be a promising drug candidate for cancer therapy.

  DOI：

  10.1021/acs.jmedchem.8b00209
• 作为产物：
  描述：

  methyl 6-(4-((tert-butoxycarbonyl)amino)benzamido)hexanoate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以0.30g的产率得到methyl 6-(4-aminobenzamido)hexanoate
  参考文献：
  名称：

  [EN] HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF
  [FR] ACIDES HYDROXAMIQUES HÉTÉROCYCLIQUES COMME INHIBITEURS DE PROTÉINE DÉSACÉTYLASE ET INHIBITEURS DOUBLES DE PROTÉINE KINASE-PROTÉINE DÉSACÉTYLASE, ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及一种新型的羟羧胺酸，它们是特异的组蛋白去乙酰化酶（HDAC）抑制剂和/或TTK/Mps1激酶抑制剂，包括其药用盐，用于调节HDAC和/或TTK/Mps1激酶活性，包括这些化合物的制药组合物，以及其制备方法。

  公开号：

  WO2015175813A1

文献信息

• AMINO ACID DIAMIDES IN NON ALPHA POSITION WHICH ARE USEFUL AS ADJUVANTS FOR ADMINISTRATION OF BIOLOGICAL ACTIVE AGENTS
  申请人：Sarkis Mardiguian Jean

  公开号：US20070191302A1

  公开（公告）日：2007-08-16

  Amino acid diamides in non α position of formula (1), wherein R 1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO 2 , OH, OCH 3 alone or associated and R 2 is selected from the group consisting of functional groups H, alkyl, halogen, NO 2 , OH, OCH 3 , which are useful as adjuvants for the administration of biological active agents, as well as pharmaceutical compositions containing these diamides of formula (1) and the use thereof for the manufacture of antithrombotic medications and for the manufacture of a medication for the treatment of a disease selected from amongst the group consisting of inflammation, cancer and allergy.

  公式（1）中非α位的氨基酸二酰胺，其中R1从以下官能团组中选择，包括烷基，卤素，NO2，OH，OCH3单独或联合；R2从以下官能团组中选择，包括H，烷基，卤素，NO2，OH，OCH3，它们可用作生物活性剂的辅助剂。此外，还包括含有公式（1）的这些二酰胺的制药组合物及其用于制造抗血栓药物和治疗炎症，癌症和过敏等疾病的药物的用途。
• Amino acid diamides in non α position which are useful as adjuvants for administration of biological active agents
  申请人：Laboratorios Farmaceuticos Rovi, S.A.

  公开号：US07462735B2

  公开（公告）日：2008-12-09

  Amino acid diamides in non α position of formula (1), wherein R1 is selected from amongst the group consisting of the functional groups alkyl, halogen, NO2, OH, OCH3 alone or associated and R2 is selected from the group consisting of functional groups H, alkyl, halogen, NO2, OH, OCH3, which are useful as adjuvants for the administration of biological active agents, as well as pharmaceutical compositions containing these diamides of formula (1) and the use thereof for the manufacture of antithrombotic medications and for the manufacture of a medication for the treatment of a disease selected from amongst the group consisting of inflammation, cancer and allergy.

  公式（1）中非α位的氨基酸二酰胺，其中R1从以下官能团组中选择，包括仅为或结合的烷基，卤素，NO2，OH，OCH3，而R2从以下官能团组中选择，包括H，烷基，卤素，NO2，OH，OCH3，这些二酰胺可用作生物活性剂的辅料，以及包含公式（1）的这些二酰胺的制药组合物，以及其用于制造抗血栓药物和治疗炎症，癌症和过敏等疾病的药物的用途。
• AMINO ACID DIAMIDES IN NON ALPHA POSITION USEFUL AS ADJUVANTS FOR THE ADMINISTRATION OF ACTIVE BIOLOGICAL AGENTS
  申请人：LABORATORIOS FARMACEUTICOS ROVI, S.A.

  公开号：EP1652836B1

  公开（公告）日：2007-07-18
• HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：The Regents of the University of Colorado, a body corporate

  公开号：EP3142652A1

  公开（公告）日：2017-03-22
• Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof
  申请人：The Regents of the University of Colorado, A Body Corporate

  公开号：US20170081343A1

  公开（公告）日：2017-03-23

  The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.